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Southern Africa is a research-rich environment in which research 
ethics review is critical. The research ethics review system is well 
establsihed but considerable variability in capacity and training 
exists among the various research ethics committees (RECs) in 
the region. The ARESA programme comprises a Postgraduate 
Diploma in Health Research Ethics, an annual seminar, a 
newsletter and an association of REC members. The programme 
has been developed to promote health in the region via capacity 
development in the field of research ethics.
Southern Africa is regarded as fertile ground for a wide range 
of research endeavours because of the enormous burden of 
infectious disease in the region, highly skilled yet poorly paid 
medical researchers, a modest ethics review infrastructure 
and large numbers of treatment-naïve patients.1,2 South Africa 
is positioned at the epicentre of the HIV pandemic and HIV 
research is flourishing scientifically but often floundering from 
an ethics perspective. Since 1997, the controversial HIV vertical 
transmission trials have raised questions about standards of care 
and placebo use.3,4 HIV vaccine research raised a host of new 
ethical questions such as the clade of HIV that should be tested 
in southern Africa, educational thresholds of participants in high-
risk phase 1 trials, stigmatisation of participants, and risk-benefit 
ratios of trials on candidate vaccines, inter alia.5-7 Microbicide 
research has experienced major scientific and ethical setbacks,8-13 
and the Orange Farm study on circumcision and HIV prevention 
(Gauteng, South Africa), in particular, raised major ethical concerns 
and resulted in The Lancet declining publication of results.14,15 
Most recently, the release of results on patients co-infected with 
tuberculosis and HIV – the SAPIT trial – sparked an international 
bioethics debate on the vulnerability of research participants, 
clinical equipoise and the quality of research ethics review in South 
Africa.16 The editorial referring to the SAPIT trials in the Hastings 
Centre Report (April 2010) was entitled ‘The study that should not 
have been done’ – a damning indictment of HIV/TB researchers in 
South Africa and the local research ethics committee (REC) that 
approved the study.17 Apart from HIV research, TB studies also 
raise ethical concerns in southern Africa. Large community-based 
studies using community randomisation methods are scientifically 
challenging. Home-based research raises questions about privacy 
and confidentiality, as well as issues related to field worker safety. 
Community stigmatisation is another important but often neglected 
social risk.
In addition to infectious disease research, a wide range of other 
chronic diseases (asthma, hypertension, diabetes, ischaemic heart 
disease) are studied in southern Africa – largely because of the vast 
populations of treatment-naïve patients in the region. In addition 
the generally poor availability of care at public hospitals and clinics 
in the region makes research projects a more attractive option to 
participants who perceive such projects to offer a higher standard of 
care even if a placebo arm forms part of the research design.
Given the dramatic rise in research activities involving humans in 
southern Africa, participant protection and RECs are priorities.18 
The recent update of the Declaration of Helsinki deserves more 
attention in developed and developing countries alike, especially 
in respect of post-trial obligations.19 Global responsibility in 
establishing a culture of excellence in research ethics review 
remains vital.20 In South Africa, the last empirical review of RECs 
was conducted in 2003. Survey findings indicated that the ethics 
review system in South Africa is functioning at a reasonable 
level, but there is wide variation among committees. RECs are 
geographically distant and function in isolation without opportunity 
to communicate and share ideas. Among institutional RECs, 
there was a stark contrast between historically disadvantaged 
institutions and historically advantaged institutions. Nearly a 
decade after the democratic elections, REC membership was 
still dominated by white males. Community representation was 
inadequate. Domination of RECs by scientists and clinicians was 
pervasive. The review process was widely variable with delays 
in review ranging from 10 days to 10 weeks. Procedural and 
bureaucratic demands appeared to impact on the ability of REC 
members to engage in debate on important substantive ethics 
issues like standards of care, informed consent and participant 
remuneration. Research ethics training and educational needs 
varied widely across the country.21 The recent debacle over the 
SAPIT trial has highlighted the need for more extensive research 
ethics training in southern Africa.
ARESA programme vision 
The goal of building capacity in research ethics in southern Africa 
cannot and should not be distinguished from the related goals of 
improving the health and well-being of populations, combating social 
injustice, and defending human rights. Over the past decade the 
interrelatedness of these goals has become increasingly obvious. 
Background conditions of poverty, gender inequality, discrimination, 
inadequate sanitation, lack of food security, political and criminal 
violence and a host of other factors are well-established determinants 
of poor health. As the history of South Africa has made abundantly 
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clear, poor population health is not randomly distributed, but is due 
in large part to political decisions and socio-economic forces. Both 
health research and structural interventions are required to improve 
health conditions, but conducting effective and ethically responsible 
health research in such circumstances is fraught with challenges. In 
southern Africa, considerations of social justice and human rights 
cannot be separated from the endeavour of conducting ethically 
responsible research or from the important task of reviewing health 
research from an ethical and regulatory perspective. This ethical 
vision has informed curriculum development, education, mentorship 
and network-building activities of the ARESA capacity-building 
programme.
The ARESA programme
The central mission of the ARESA programme is to build capacity 
and enhance expertise in research ethics and bioethics primarily 
through a comprehensive and locally relevant Postgraduate Diploma 
in Health Research Ethics targeting experienced researchers, 
clinicians, academics and REC members from southern Africa. The 
educational programme consists of a structured array of practical 
experiences and career-development activities directly relevant to the 
ethical analysis and review of research involving human participants 
in resource-constrained settings. The diploma programme consists 
of three 2-week modules over the course of a year. The first module 
introduces trainees to the history and major principles of research 
ethics, philosophical ethics (both western and African), health law 
and human rights. The second module is devoted to the neglected 
theme of dual (scientific and ethical) review of research. Trainees 
are introduced to the basis of research methodology, design and trial 
phases, and how these elements are inseparably linked to ethical 
issues in research. Attention is also devoted to scientific integrity 
and publication ethics. The final module explores the concept of 
vulnerability by examining the research and public health ethics 
issues arising from certain research areas (genetics, oncology and 
infectious disease) and specific study populations (children, mental 
health patients, geriatric patients). 
The postgraduate diploma programme will be reinforced and 
complemented by supplementary goals: holding an annual research 
ethics seminar, establishing an association of REC members in 
southern Africa, developing new research ethics curricula, and 
disseminating research ethics news and information through the 
ARESA newsletter. The ARESA Research Ethics Seminar will 
be held over 2 days annually in Cape Town. The first seminar is 
scheduled for 30-31 August 2012, and it is anticipated that 120 
delegates from the South African research ethics community will 
attend. A vibrant programme supported by international and national 
invited speakers will be presented. The development of a Research 
Ethics Committee Association responds to the need to enhance 
networking and information exchange among members of RECs 
in southern Africa. The association will also have an educational 
function in developing and maintaining a list of research ethics 
resources and online short training courses. Training on the ARESA 
programme is limited to 10 trainees per academic year, but some 
modules are offered as short courses as well. The planned ARESA 
newsletter will be trainee-driven, and two issues will be circulated 
electronically each academic year. The ARESA programme is 
funded by the Fogarty International Center at the US National 
Institutes of Health and is a collaboration between the University 
of Stellenbosch and the University of North Carolina at Chapel Hill, 
USA. 
Conclusion
Research activities in southern Africa threaten to outpace 
local capacity in research ethics. The new ARESA programme 
aims to enhance practical skills by exposing trainees to 
fundamentals of research ethics, REC deliberations and 
conducting protocol review exercises. An important outcome 
is the development of a package of research ethics training 
materials by trainees for their home institutions. The 
programme hopes to contribute to a culture of ethically 
responsible research in southern Africa through network 
development, dissemination of information, public awareness 
and outreach. 
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